Pharma marketers are facing a new level of uncertainty around direct-to-consumer advertising in the U.S.. On July 23, 2026, the non-profit consumer rights advocacy group Public Citizen petitioned the FDA to ban direct-to-consumer advertising of prescription drugs. Just earlier that month, the FDA included a planned rule in its 2026 Unified Agenda that would eliminate the adequate-provision pathway that has helped make broadcast DTC advertising viable for nearly 30 years. These developments do not change the rules today, but they should influence how brands plan for tomorrow.
We’re facing a regulatory, media, measurement, creative, and operational challenge where the capabilities needed to respond will require significant time to build. If the FDA proceeds with the rule as currently described, traditional broadcast advertising could become significantly more difficult and expensive. Brands would need to reach patients and caregivers through a broader mix of channels, stronger data partnerships, and more intricate measurement.
The right response is disciplined scenario planning. Brands that begin preparing now may find themselves with a competitive advantage as the regulatory environment develops.
What the Adequate-Provision Standard Means
Since 1997, FDA guidance has allowed prescription drug advertisements on television and radio to satisfy certain disclosure obligations by presenting the major statement of risks within the advertisement and directing consumers to other sources for the complete prescribing information. Those sources may include a website, a toll-free telephone number, a concurrent print advertisement, or a healthcare professional. This adequate-provision pathway helped make broadcast DTC advertising practical.
The FDA’s planned rulemaking would revise 21 CFR 202.1 and eliminate the option to satisfy the brief-summary requirement through a source outside the advertisement. Depending on the language of the final revisions, broadcast advertisements could be required to include substantially more safety information within the advertisement itself, thus making traditional television and radio advertisements longer, more complex, and more expensive to produce and place. Some legal and regulatory experts have described the potential result as a de facto restriction on broadcast DTC advertising.
The regulatory process is still developing. The FDA has listed the action in the Unified Agenda, with a proposed rule currently anticipated in December 2026. Publication of a Notice of Proposed Rulemaking would begin a formal process that typically includes public comments, regulatory analysis, and potential revisions before a final rule could take effect.
A Broader Period of DTC Scrutiny
The adequate-provision issue is part of a larger shift in the regulatory and political environment surrounding pharmaceutical advertising. In September 2025, the FDA announced an enforcement initiative focused on deceptive or misleading prescription drug promotion. The agency issued approximately 100 cease-and-desist letters and thousands of warning letters while expanding its scrutiny of DTC promotion across traditional and digital channels.
Legislative proposals have added another layer of uncertainty. The Responsibility in Drug Advertising Act would restrict DTC advertising during the first three years following a drug’s approval. Other proposals have called for broader restrictions across television, radio, print, digital, and social media.
The path forward for these proposals remains uncertain. Each scenario could have a meaningful effect on launch planning, particularly during the early adoption period when patient awareness and HCP education are both critical.
Brands with products in development or approaching launch should model the potential impact now. A three-year restriction on consumer promotion, for example, could shift early investment toward HCP engagement, disease education, patient support, point of care and other appropriate channels – increasing competition in those spaces which would, in turn, drive up the cost.
Media Investment Was Already Evolving
Pharmaceutical media investment has been moving toward digital and addressable channels for several years.
MM+M’s Healthcare Marketers Trends Report 2026 found that digital advertising investment is expected to exceed linear television spending in the category for the first time this year. The report also found that 58 percent of pharmaceutical marketers plan to increase connected television investment.
Fierce Pharma’s 2026 forecast estimates $26.2 billion in pharmaceutical digital spending, compared with $6.9 billion in traditional media. Connected television is also projected to surpass linear television spending in the category by 2028.
The planned FDA rule could accelerate a transition that is already underway. This evolution gives brands an opportunity to build media plans with greater audience precision, more flexibility, and stronger connections between exposure and meaningful healthcare actions. Success will depend on how well the channels work together across the patient and HCP journey.
Three Priorities for a More Resilient Media Plan
Connected and Addressable Television
Connected television can preserve the reach and storytelling power of video while offering more precise audience targeting, frequency management, and household-level measurement.
According to eMarketer research, 51 percent of U.S. consumers reported seeing healthcare and pharmaceutical advertising on connected television, up from 41.8 percent the previous year. That level of visibility reflects how quickly viewing behavior is changing. Brands should evaluate connected television inventory carefully. Audience quality, device type, format, disclosure requirements, measurement capabilities, and regulatory treatment can vary across platforms and publishers. Legal and regulatory partners should be involved as the industry receives further guidance about how future requirements may apply across streaming environments.
CTV can play an important role in the future mix, especially when it is connected to search, point of care, patient education, and other channels that help audiences take the next appropriate step. Digital attribution will become even more essential.
Point of Care
Point-of-care media reaches patients during moments when health information is especially relevant. The channel now includes physician offices, pharmacies, telehealth platforms, electronic health records, and emerging clinical tools. According to Point of Care Marketing Association member data, the category has been growing by approximately 22 percent annually and exceeded $1 billion in revenue in 2024.
Point of care can support education, help patients prepare for productive conversations, and connect media exposure more closely with healthcare activity. It can also complement broader awareness channels by reinforcing information when patients and caregivers are actively engaging with the healthcare system.
Its role should be evaluated based on the treatment journey, care setting, audience size, and availability of meaningful measurement.
HCP Engagement
Prescribers and other healthcare professionals will continue to play a central role in patient education, diagnosis, treatment decisions, access, and ongoing care. For launch brands, early HCP awareness and confidence will increase in importance.
Effective HCP engagement extends across paid search, professional media, programmatic targeting, endemic platforms, EHR placements, point of care, congress activity, and other relevant channels. The mix should reflect how each specialty consumes information and how individual HCPs influence the patient journey.
HCP and patient strategies should share a common foundation. Messaging, audience insights, measurement, and timing should connect across both sides of the plan so that each channel reinforces the broader brand objective.
Build the Measurement Plan Early
Broadcast television has never provided perfect measurement, but brands understand its currency, benchmarks, and role within the media mix. Moving investment into several addressable channels introduces different data sources, attribution models, and definitions of success.
Brands should define the primary business outcome before changing the channel mix. Depending on the product and launch stage, that outcome could include qualified website activity, patient-support engagement, HCP actions, new-patient starts, prescription lift, or another agreed-upon downstream measure.
Every channel may play a different role in achieving that outcome, so the measurement framework should account for those roles while maintaining a consistent view of overall performance.
This work should begin concurrently with media planning. Data agreements, privacy reviews, tagging, clean-room capabilities, match methodologies, and reporting standards often take longer to establish than expected. Early planning gives teams the time to identify limitations and set realistic expectations with internal stakeholders.
Prepare for a Greater Creative and MLR Burden
Linear television often centers on a limited number of high-reach executions. Addressable video, social platforms, paid search, point of care, HCP media, and programmatic channels require different specifications, messages, audience variations, and refresh schedules. That creates additional work for creative, legal, medical, and regulatory teams. Brands should evaluate their approval process alongside their channel strategy.
Modular creative can help. Developing preapproved components, message frameworks, claims libraries, and channel-specific templates can make it easier to create appropriate variations while maintaining consistency and compliance.
Search and AI Are Changing How Audiences Find Health Information
The way patients, caregivers, and HCPs discover information is also evolving. Conductor’s 2026 healthcare benchmarks found that AI Overviews appear on 49% of first-page Google queries in healthcare. The same research found that ChatGPT accounts for 84% of healthcare referral traffic from AI platforms.
AI referral traffic still represents a small portion of total healthcare website traffic. Its influence reaches beyond direct clicks because search engines and AI tools increasingly answer questions within the results experience.
This makes credible, well-structured, and clearly sourced content more important. Disease education, expert commentary, earned media, and useful brand resources can all contribute to visibility when audiences ask health-related questions.
Brands should consider answer-engine visibility as part of their broader media and content strategy. Paid, owned, and earned efforts should work together to help accurate information appear when patients and HCPs are actively seeking answers.
What Brands Should Do in the Next 90 Days
Brands can take several practical steps while the regulatory process develops:
- Model multiple scenarios, including limited regulatory change, a restriction on broadcast DTC, and a broader launch-stage DTC limitation.
- Audit how much planned reach and frequency depend on linear television.
- Identify which audience, data, technology, measurement, and publisher partnerships would take the longest to establish.
- Build or strengthen disease-state audiences that can support communication across multiple regulatory outcomes.
- Review HCP investment levels, audience coverage, channel roles, and connections to the patient journey.
- Evaluate MLR capacity for a media plan requiring more formats, messages, and creative variations.
- Establish one primary downstream outcome and a shared measurement framework before campaigns launch.
- Develop budget reallocation rules so teams understand what events would trigger a change and how investment would move.
- Prepare to participate in the FDA comment period if and when the Notice of Proposed Rulemaking is published. Brand, media, and marketing perspectives can provide valuable input into the practical implications of the proposed requirements.
The Bottom Line
The future of DTC advertising remains uncertain. The planned FDA rule could change during the regulatory process, face legal challenges, or ultimately take a different form. Pending legislation and the Public Citizen petition may also follow several possible paths.
But brands still need a plan.
Preparation for a more restricted DTC environment can produce a more targeted, measurable, and adaptable media strategy. It can also reduce the risk of losing valuable time during the most important phase of a product launch. The next era of pharmaceutical media will be shaped by how effectively brands connect audiences, channels, content, and measurement around the moments that matter.
At Silverlight Digital, we help healthcare and pharmaceutical brands build flexible media strategies grounded in audience understanding, channel expertise, and measurable outcomes. For teams planning an upcoming launch, this is the right time to evaluate how the plan would perform across several possible futures.
